Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 11:31 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2065–2088 of 26,669 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: CTRL Clear all

Conditions: Major Depressive Disorder, Alcohol Use Disorder
Interventions: allogeneic human mesenchymal stem cells (allo-hMSCs), Placebo; Drug
Lead sponsor: Ihsan M Salloum, MD, MPH; Other
Eligibility: 18 Years to 75 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 1
States / cities: Harlingen, Texas

Conditions: Total Knee Arthroplasty
Interventions: Ambulatory continuous femoral nerve block for 100 hours; Procedure
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years to 75 Years
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 3
States / cities: Berkeley, California • San Diego, California • Gainesville, Florida

Conditions: Acute Ischemic Stroke
Interventions: J147 Emulsion for Injection, Placebo; Drug · Other
Lead sponsor: Abrexa Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 196 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 5
States / cities: Long Beach, California • Rockford, Illinois • Albany, New York + 2 more

Conditions: Infertility, Female, Deferred Childbearing
Interventions: Investigational Oocyte Cryopreservation; Procedure
Lead sponsor: University of Illinois Chicago; Other
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 29 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2023
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Treatment Resistant Depression
Interventions: Synergy, Epidural cortical stimulation; Device
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 21 Years to 80 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2028
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Degenerative Lesion of Articular Cartilage of Knee
Interventions: ADSC Application, Microfracture; Procedure
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 50 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2025
U.S. locations: 3
States / cities: Redwood City, California • Santa Monica, California • Denver, Colorado

Conditions: Depression - Major Depressive Disorder, Transcranial Alternating Current Stimulation
Interventions: Closed-loop tACS, Sham Comparator; Device
Lead sponsor: Pulvinar Neuro, LLC; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Candidiasis, Vulvovaginal, Yeast Infection, Mycoses, Moniliasis, Vulvovaginal, Vaginitis, Monilial
Interventions: Not listed
Lead sponsor: Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA); Industry
Eligibility: 18 Years and older · Female only
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 23
States / cities: Phoenix, Arizona • Little Rock, Arkansas • San Diego, California + 18 more

Conditions: Basal Cell Nevus Syndrome
Interventions: Patidegib Topical Gel, 2%, Patidegib Topical Gel, Vehicle; Drug
Lead sponsor: Sol-Gel Technologies, Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 174 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 22
States / cities: Phoenix, Arizona • Newport Beach, California • Redwood City, California + 19 more

Conditions: HIV Infection, Inflammation, Cardiovascular Disease, HIV Infections
Interventions: raltegravir, Placebo; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 1
States / cities: San Francisco, California

Conditions: EBV Viremia, CMV Viremia
Interventions: Valganciclovir, Placebo; Drug
Lead sponsor: University of Minnesota; Other
Eligibility: 6 Months and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Migraine With Aura
Interventions: Partial Rebreathing Device, Sham breathing device; Device
Lead sponsor: Rehaler; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 142 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 9
States / cities: Palo Alto, California • Pasadena, California • Riverside, California + 6 more

Conditions: Esophageal Squamous Cell Carcinoma (ESCC)
Interventions: Tislelizumab, Paclitaxel, Docetaxel, Irinotecan; Drug
Lead sponsor: BeiGene; Industry
Eligibility: 18 Years and older
Enrollment: 512 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 2
States / cities: Detroit, Michigan • Toledo, Ohio

Conditions: Immune Thrombocytopenia (ITP)
Interventions: Placebo, Lusutrombopag; Drug
Lead sponsor: Shionogi; Industry
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 19
States / cities: Anaheim, California • Los Angeles, California • Washington D.C., District of Columbia + 15 more

Conditions: Colitis, Ulcerative
Interventions: Etrolizumab, Placebo; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 359 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 33
States / cities: Orange, California • San Diego, California • San Francisco, California + 29 more

Conditions: Hypertension
Interventions: LCI699, Eplerenone, LCI699-matching Placebo, Eplerenone-matching Placebo; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 155 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 37
States / cities: Mobile, Alabama • Sierra Vista, Arizona • Buena Park, California + 34 more

Conditions: Overweight, Obesity
Interventions: Macupatide, Eloralintide, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 40
States / cities: Chandler, Arizona • Scottsdale, Arizona • Tucson, Arizona + 37 more

Conditions: Alopecia Areata
Interventions: Deuruxolitinib, Placebo; Drug
Lead sponsor: Sun Pharmaceutical Industries, Inc.; Industry
Eligibility: 12 Years to 17 Years
Enrollment: 355 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 54
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Bryant, Arkansas + 44 more

Conditions: Major Depressive Disorder
Interventions: 5-hydroxytryptophan and Creatine, Placebo control; Drug · Other
Lead sponsor: Brent Michael Kious, MD, PhD; Other
Eligibility: 25 Years to 40 Years · Female only
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Depressive Disorder, Major
Interventions: Levomilnacipran ER, Placebo; Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 644 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 47
States / cities: Birmingham, Alabama • Dothan, Alabama • Phoenix, Arizona + 41 more

Conditions: Primary Insomnia
Interventions: Eszopiclone, Placebo; Drug
Lead sponsor: Duke University; Other
Eligibility: 21 Years to 64 Years
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Erectile Dysfunction
Interventions: avanafil, Placebo; Drug
Lead sponsor: VIVUS LLC; Industry
Eligibility: 18 Years to 45 Years · Male only
Enrollment: 181 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2014
U.S. locations: 15
States / cities: Huntsville, Alabama • Los Angeles, California • San Diego, California + 12 more

Conditions: Gastrointestinal Discomfort, Bloating
Interventions: Active: Multi-strain probiotic dietary supplement, Placebo: Placebo; Dietary Supplement
Lead sponsor: Daily Nouri; Industry
Eligibility: 25 Years to 45 Years · Female only
Enrollment: 160 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Arthritis, Rheumatoid
Interventions: CP-690,550, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 399 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 36
States / cities: Birmingham, Alabama • Los Angeles, California • San Diego, California + 29 more

Search by objective public record fields.

Allogeneic Human Mesenchymal Stem Cell Infusion vs Placebo in Alcohol Use Disorder and Major Depression.

Effect of Ambulatory Continuous Femoral Nerve Blocks on Readiness-for-Discharge Following Total Knee Replacement

Safety and Efficacy of J147 in Acute Ischemic Stroke

Investigational Oocyte Cryopreservation for Medical and Non Medical Indications

Epidural Cortical Stimulation for Depression

Microfracture Versus Adipose Derived Stem Cells for the Treatment of Articular Cartilage Defects

Individualized Non-invasive Brain Stimulation for the Treatment of Major Depressive Disorder

Non-Interventional Extension to Investigate Recurrence of Vulvovaginal Candidiasis and Candida Colonization

Study of Patidegib Topical Gel, 2%, for the Reduction of Disease Burden of Persistently Developing Basal Cell Carcinomas (BCCs) in Subjects With Basal Cell Nevus Syndrome (Gorlin Syndrome)

Effect of Raltegravir on Endothelial Function in HIV-Infected Patients

Treating Kidney Donors With Valganciclovir to Reduce Viral Transmission to Recipients

PArtial REbreathing for Migraine With Aura 1

A Study of Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma

A Study to Investigate the Efficacy and Safety of Lusutrombopag (S-888711) Tablets Administered to Adults With Immune Thrombocytopenia (ITP)

A Study of the Efficacy and Safety of Etrolizumab Treatment in Maintenance of Disease Remission in Ulcerative Colitis (UC) Participants Who Are Naive to Tumor Necrosis Factor (TNF) Inhibitors

A Study to Evaluate the Efficacy and Safety of LCI699 Compared to Placebo in Participants With Resistant Hypertension

A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight

Study to Evaluate the Efficacy and Safety of Deuruxolitinib in Adolescents With Severe Alopecia Areata

Placebo-controlled Trial of 5-hydroxytryptophan and Creatine for SSRI or SNRI Augmentation in Treatment Resistant Depression in Females

A Multicenter, Relapse Prevention Study With Levomilnacipran Extended Release (ER) in Participants With Major Depressive Disorder

Study of the Insomnia in Patients With Low Back Pain

Study Evaluating the Effects of Avanafil on Semen Parameters

Multi-strain Probiotic Supplement for Digestive Comfort and Well-being in Healthy Women

Study of CP-690,550 Versus Placebo In Rheumatoid Arthritis Patients On Background Methotrexate With Inadequate Response To Tumor Necrosis Factor (TNF) Inhibitors